1YV5
Human farnesyl diphosphate synthase complexed with Mg and risedronate
1YV5 の概要
エントリーDOI | 10.2210/pdb1yv5/pdb |
関連するPDBエントリー | 1YQ7 |
分子名称 | Farnesyl pyrophosphate synthetase, MAGNESIUM ION, PHOSPHATE ION, ... (5 entities in total) |
機能のキーワード | isoprenoid pathway, cholesterol synthesis, bisphosphonate, structural genomics, structural genomics consortium, sgc, transferase |
由来する生物種 | Homo sapiens (human) |
細胞内の位置 | Cytoplasm: P14324 |
タンパク質・核酸の鎖数 | 1 |
化学式量合計 | 43559.75 |
構造登録者 | Kavanagh, K.L.,Guo, K.,Von Delft, F.,Arrowsmith, C.,Sundstrom, M.,Edwards, A.,Oppermann, U.,Structural Genomics Consortium (SGC) (登録日: 2005-02-15, 公開日: 2005-03-01, 最終更新日: 2023-10-25) |
主引用文献 | Kavanagh, K.L.,Guo, K.,Dunford, J.E.,Wu, X.,Knapp, S.,Ebetino, F.H.,Rogers, M.J.,Russell, R.G.,Oppermann, U. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc.Natl.Acad.Sci.USA, 103:7829-7834, 2006 Cited by PubMed Abstract: Osteoporosis and low bone mass are currently estimated to be a major public health risk affecting >50% of the female population over the age of 50. Because of their bone-selective pharmacokinetics, nitrogen-containing bisphosphonates (N-BPs), currently used as clinical inhibitors of bone-resorption diseases, target osteoclast farnesyl pyrophosphate synthase (FPPS) and inhibit protein prenylation. FPPS, a key branchpoint of the mevalonate pathway, catalyzes the successive condensation of isopentenyl pyrophosphate with dimethylallyl pyrophosphate and geranyl pyrophosphate. To understand the molecular events involved in inhibition of FPPS by N-BPs, we used protein crystallography, enzyme kinetics, and isothermal titration calorimetry. We report here high-resolution x-ray structures of the human enzyme in complexes with risedronate and zoledronate, two of the leading N-BPs in clinical use. These agents bind to the dimethylallyl/geranyl pyrophosphate ligand pocket and induce a conformational change. The interactions of the N-BP cyclic nitrogen with Thr-201 and Lys-200 suggest that these inhibitors achieve potency by positioning their nitrogen in the proposed carbocation-binding site. Kinetic analyses reveal that inhibition is competitive with geranyl pyrophosphate and is of a slow, tight binding character, indicating that isomerization of an initial enzyme-inhibitor complex occurs with inhibitor binding. Isothermal titration calorimetry indicates that binding of N-BPs to the apoenzyme is entropy-driven, presumably through desolvation entropy effects. These experiments reveal the molecular binding characteristics of an important pharmacological target and provide a route for further optimization of these important drugs. PubMed: 16684881DOI: 10.1073/pnas.0601643103 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (2 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード